Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Effect of Valve Type and Anesthesia Strategy for TAVR: 5-Year Results of the SOLVE-TAVI Trial

  • Heart Center Leipzig at Leipzig University
  • Universität Leipzig
  • Helios Health Institute

Abstract

BACKGROUND: In the randomized SOLVE-TAVI (compariSon of secOnd-generation seLf-expandable vs. balloon-expandable Valves and gEneral vs. local anesthesia in Transcatheter Aortic Valve Implantation) trial comparing newer-generation self-expanding valves (SEV) and balloon-expandable valves (BEV), as well as conscious sedation (CS) and general anesthesia (GA), clinical outcomes were similar both for valve and anesthesia comparison at 30 days and 1 year. Prosthesis durability may affect clinical outcomes during long-term follow-up. Moreover, the impact of the anesthesia strategy on long-term clinical outcomes is unknown so far.

OBJECTIVES: The authors sought to compare clinical outcomes during 5-year follow-up in the randomized SOLVE-TAVI trial.

METHODS: In the randomized, multicenter, 2 × 2 factorial, open-label SOLVE-TAVI trial, 447 intermediate- to high-risk patients with severe, symptomatic aortic stenosis were randomly assigned to transfemoral transcatheter aortic valve replacement (TAVR) using either SEV (Evolut R, Medtronic) or BEV (SAPIEN 3, Edwards Lifesciences) and also to CS vs GA. Patients were followed-up for 5 years.

RESULTS: During 5 years of follow-up, the combined predefined endpoint of all-cause mortality, stroke, moderate or severe paravalvular leakage, and permanent pacemaker implantation was similar in the SEV and BEV groups (67.7% vs 63.4%; HR: 0.89; 95% CI: 0.70-1.13; P = 0.34). Stroke rates at 5 years were lower in the SEV group (2.2% vs 9.6%; HR: 4.84; 95% CI: 1.65-14.18; P = 0.002). Regarding the anesthesia comparison, the primary endpoint of all-cause mortality, stroke, myocardial infarction, and acute kidney injury occurred in 51.4% in the CS group and 61.3% in the GA group (HR: 0.80; 95% CI: 0.62-1.04; P = 0.09). All-cause mortality at 5 years was lower for CS (41.5% vs 54.3%; HR: 0.70; 95% CI: 0.53-0.94; P = 0.02).

CONCLUSIONS: Transfemoral TAVR using either SEV and BEV as well as CS and GA showed similar clinical outcomes at 5 years using a combined clinical endpoint.

OriginalspracheEnglisch
ZeitschriftJournal of the American College of Cardiology
Jahrgang85
Ausgabenummer1
Seiten (von - bis)74-82
Seitenumfang9
ISSN0735-1097
DOIs
PublikationsstatusVeröffentlicht - 07.01.2025

Fördermittel

The design of the SOLVE-TAVI trial has been described in detail previously. 8 , 13 In brief, SOLVE-TAVI is an investigator-initiated, open-label, prospective, randomized, multicenter trial conducted at 7 German sites including patients with severe, symptomatic aortic stenosis scheduled for transfemoral TAVR. Patients \u226575 year of age and at intermediate-to-high risk for conventional surgery were eligible for the trial. Adopting a 2 \u00D7 2 factorial design, patients were randomized to either a SEV (Evolut R) or BEV (SAPIEN 3), as well as CS or GA. The trial was designed independently by the principal investigator in cooperation with the steering committee and coordinated by the Helios Health Institute (formerly Leipzig Heart Institute) and the Center for Clinical Trials at University of L\u00FCbeck. Data management and statistics were performed by the Institute of Medical Biometry and Statistics (IMBS) at University of L\u00FCbeck. Funding was provided by the German Heart Research Foundation and the Helios Health Institute.

Träger
Deutsche Stiftung für Herzforschung
Helios Health Institute

    UN SDGs

    Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

    1. SDG 3 – Gesundheit und Wohlergehen
      SDG 3 – Gesundheit und Wohlergehen

    Strategische Forschungsbereiche und Zentren

    • Zentren: Universitäres Herzzentrum Lübeck (UHZL)

    DFG-Fachsystematik

    • 2.22-12 Kardiologie, Angiologie
    • 2.22-11 Anästhesiologie

    Fingerprint

    Untersuchen Sie die Forschungsthemen von „Effect of Valve Type and Anesthesia Strategy for TAVR: 5-Year Results of the SOLVE-TAVI Trial“. Zusammen bilden sie einen einzigartigen Fingerprint.

    Dieses zitieren